文献速递垂体与肾上腺疾病

肾上腺意外瘤患者血浆类固醇谱分析

Plasma Steroid Profiling in Patients With Adrenal Incidentaloma.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项回顾性横断面研究纳入577例肾上腺意外瘤患者,评估血浆类固醇谱联合甲氧基肾上腺素和肿瘤大小对鉴别诊断的价值。结果显示该组合可高灵敏度、高特异性地识别肾上腺皮质癌、原发性醛固酮增多症和嗜铬细胞瘤,联合肿瘤大小后鉴别效果进一步提升,但对自主皮质醇分泌和非功能性意外瘤的鉴别仍不理想。

要点

  • 血浆类固醇谱联合甲氧基肾上腺素可高灵敏度识别肾上腺皮质癌、原发性醛固酮增多症和嗜铬细胞瘤。
  • 联合肿瘤大小后,肾上腺皮质癌鉴别灵敏度达100%、特异度99.5%。
  • 对自主皮质醇分泌和非功能性意外瘤的鉴别仍欠佳,灵敏度70%-71%、特异度89%-90%。

核心结论

  • 血浆类固醇代谢组学联合常规血浆游离甲氧基肾上腺素和影像学数据,可能有助于识别几乎全部临床相关的肾上腺肿瘤。

研究设计与样本

  • 回顾性横断面研究,在7个欧洲三级医疗中心纳入577例肾上腺意外瘤患者,包括肾上腺皮质癌19例、嗜铬细胞瘤77例、原发性醛固酮增多症65例、自主皮质醇分泌104例和非功能性意外瘤312例。

主要发现

  • 肾上腺皮质癌患者血浆11-脱氧皮质醇、11-脱氧皮质酮、17-羟孕酮、雄烯二酮和硫酸脱氢表雄酮浓度升高。
  • 原发性醛固酮增多症患者醛固酮、18-氧代皮质醇和18-羟基皮质醇升高。
  • 8种类固醇联合皮质醇、皮质酮、脱氢表雄酮及血浆甲氧基肾上腺素,识别肾上腺皮质癌、原发性醛固酮增多症和嗜铬细胞瘤的灵敏度分别为83.3%(66.1%-100%)、90.8%(83.7%-97.8%)和94.8%(89.8%-99.8%),特异度分别为98.0%(96.9%-99.2%)、92.0%(89.6%-94.3%)和98.6%(97.6%-99.6%)。
  • 联合肿瘤大小后鉴别效果进一步提升,尤其对肾上腺皮质癌灵敏度达100%(100%-100%)、特异度99.5%(98.9%-100%)。
  • 对自主皮质醇分泌和非功能性意外瘤的鉴别仍不理想,灵敏度70%-71%、特异度89%-90%。

关键数值与推荐

  • 肾上腺皮质癌鉴别:联合方案灵敏度83.3%(66.1%-100%)、特异度98.0%(96.9%-99.2%);联合肿瘤大小后灵敏度100%(100%-100%)、特异度99.5%(98.9%-100%)。
  • 原发性醛固酮增多症鉴别:灵敏度90.8%(83.7%-97.8%)、特异度92.0%(89.6%-94.3%)。
  • 嗜铬细胞瘤鉴别:灵敏度94.8%(89.8%-99.8%)、特异度98.6%(97.6%-99.6%)。

临床怎么用

  • 对于肾上腺意外瘤患者,可考虑检测血浆类固醇谱联合血浆游离甲氧基肾上腺素,并结合影像学肿瘤大小,以辅助鉴别肾上腺皮质癌、原发性醛固酮增多症和嗜铬细胞瘤。
  • 该联合方案对自主皮质醇分泌和非功能性意外瘤的鉴别能力有限,临床决策仍需结合其他检查综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Most patients with adrenal incidentaloma have nonfunctional lesions that do not require treatment, while others have functional or malignant tumors that require intervention. The plasma steroid metabolome may be useful to assess therapeutic need. OBJECTIVE: This work aimed to establish the utility of plasma steroid profiling combined with metanephrines and adrenal tumor size for the differential diagnosis of patients with adrenal incidentaloma. METHODS: This retrospective cross-sectional study, which took place at 7 European tertiary-care centers, comprised 577 patients with adrenal incidentaloma, including 19, 77, 65, 104 and 312 respective patients with adrenocortical carcinoma (ACC), pheochromocytoma (PHEO), primary aldosteronism (PA), autonomous cortisol secretion (ACS), and nonfunctional adrenal incidentaloma (NFAI). Mesaures of diagnostic performance were assessed (with [95% CIs]) for discriminating different subgroups of patients with adrenal incidentaloma. RESULTS: Patients with ACC were characterized by elevated plasma concentrations of 11-deoxycortisol, 11-deoxycorticosterone, 17-hydroxyprogesterone, androstenedione, and dehydroepiandrosterone-sulfate, whereas patients with PA had elevations of aldosterone, 18-oxocortisol, and 18-hydroxycortisol. A selection of those 8 steroids, combined with 3 others (cortisol, corticosterone, and dehydroepiandrosterone) and plasma metanephrines, proved optimal for identifying patients with ACC, PA, and PHEO at respective sensitivities of 83.3% (66.1%-100%), 90.8% (83.7%-97.8%), and 94.8% (89.8%-99.8%); and specificities of 98.0% (96.9%-99.2%), 92.0% (89.6%-94.3%), and 98.6% (97.6%-99.6%). With the addition of tumor size, discrimination improved further, particularly for ACC (100% [100%-100%] sensitivity, 99.5% [98.9%-100%] specificity). In contrast, discrimination of ACS and NFAI remained suboptimal (70%-71% sensitivity, 89%-90% specificity). CONCLUSION: Among patients with adrenal incidentaloma, the combination of plasma steroid metabolomics with routinely available plasma free metanephrines and data from imaging studies may facilitate the identification of almost all clinically relevant adrenal tumors.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Berke K, Constantinescu G, Masjkur J, et al. Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. J Clin Endocrinol Metab. 2022. PMID: 34665854. doi:10.1210/clinem/dgab751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。